Adipokines in Nonalcoholic Steatohepatitis: From Pathogenesis to Implications in Diagnosis and Therapy
Open Access
- 3 June 2009
- journal article
- review article
- Published by Hindawi Limited in Mediators of Inflammation
- Vol. 2009, 1-8
- https://doi.org/10.1155/2009/831670
Abstract
Nonalcoholic fatty liver disease (NAFLD) is the hepatic manifestation of the metabolic syndrome and can vary from benign steatosis to end-stage liver disease. The pathogenesis of non-alcoholic steatohepatitis (NASH) is currently thought to involve a multiple-hit process with the first hit being the accumulation of liver fat which is followed by the development of necroinflammation and fibrosis. There is mounting evidence that cytokines secreted from adipose tissue, namely, adipokines, are implicated in the pathogenesis and progression of NAFLD. In the current review, we explore the role of these adipokines, particularly leptin, adiponectin, resistin, tumor necrosis factor-a, and interleukin-6 in NASH, as elucidated in experimental models and clinical practice. We also comment on their potential use as noninvasive markers for differentiating simple fatty liver from NASH as well as on their potential future therapeutic role in patients with NASH.Keywords
This publication has 99 references indexed in Scilit:
- Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trialThe Lancet, 2008
- Serum retinol‐binding protein 4 levels are elevated in non‐alcoholic fatty liver diseaseClinical Endocrinology, 2007
- Retinol Binding Protein 4 Expression in Humans: Relationship to Insulin Resistance, Inflammation, and Response to PioglitazoneJournal of Clinical Endocrinology & Metabolism, 2007
- Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosisJournal of Hepatology, 2007
- Resistin as an Intrahepatic CytokineThe American Journal of Pathology, 2006
- Interleukin-6 is a key mediator of the hepatoprotective and pro-proliferative effects of ischaemic preconditioning in miceJournal of Hepatology, 2006
- Systemic inflammation in nonalcoholic fatty liver disease is characterized by elevated levels of CCL2Journal of Hepatology, 2006
- Nonalcoholic Fatty Liver Disease: From Steatosis to CirrhosisHepatology, 2006
- Nonalcoholic Fatty Liver, Steatohepatitis, and the Metabolic SyndromeHepatology, 2003
- Resistin is expressed in human macrophages and directly regulated by PPARγ activatorsBiochemical and Biophysical Research Communications, 2003